Key facts
| Price (PPV) | 19,047 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | afatinib |
| Class | Antineoplastic agents |
| ATC code | L01XE13 |
| Manufacturer | BOTTU S.A. |
| Presentation | Boite de 28 |
| Hospital price | 18,682 MAD |
| Data collected on | 9/8/2026 |
Indications
GIOTRIF est indiqué en monothérapie dans les traitements suivants : - Patients adultes naïfs de TKI anti EGFR (récepteur du facteur de croissance épidermique) atteints d’un cancer bronchique non à petites cellules (CBNPC) localement avancé ou métastatique qui présente une (des) mutation(s) activatrice(s) de l’EGFR. - Patients adultes ayant un cancer bronchique non à petites cellules (CBNPC) de type épidermoïde, localement avancé ou métastatique, progressant sous ou après chimiothérapie à base de platine.
Find an open pharmacy
On-call pharmacies near you
About Giotrif 40 mg
Giotrif 40 mg belongs to the antineoplastic agents therapeutic class. In Morocco, this drug is marketed by BOTTU S.A. and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Giotrif 40 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Giotrif 40 mg
Answers to common questions from Moroccan patients about this drug.